Prostate Cell News Volume 13.23 | Oct 14 2022

    By
    Noshin Noorjahan
    -
    0
    21








    2022-10-14 | PCN 13.23


    Prostate Cell News by STEMCELL Technologies
    Vol. 13.23 – 14 October, 2022
    TOP STORY

    Targeting Androgen Receptor Phase Separation to Overcome Antiandrogen Resistance

    Scientists conducted a phase-separation-based phenotypic screen and identified ET516 that specifically disrupted androgen receptor (AR) condensates, effectively suppressed AR transcriptional activity, and inhibited the proliferation and tumor growth of prostate cancer cells expressing AR-resistant mutants.
    [Nature Chemical Biology]

    AbstractGraphical Abstract
    Explore this validated protocol for high-efficiency gene editing of Human Pluripotent Stem Cells using the ArciTectâ„¢ CRISPR-Cas9 System.
    PUBLICATIONSRanked by the impact factor of the journal

    CRISPR/Cas9-Mediated Deletion of Interleukin-30 Suppresses IGF1 and CXCL5 and Boosts SOCS3 Reducing Prostate Cancer Growth and Mortality

    Prostate cancer cell production of, and response to, IL30 was tested by flow cytometry, immunoelectron microscopy, invasion and migration assays, and PCR arrays.
    [Journal of Hematology & Oncology]

    Full Article

    Linear Ubiquitination of PTEN Impairs Its Function to Promote Prostate Cancer Progression

    Scientists found that HOIP, one important component of linear ubiquitin chain assembly complex, promoted prostate cancer progression by enhancing AKT signaling in a PTEN-dependent manner.
    [Oncogene]

    Full Article

    Inhibition of Mps1 Kinase Enhances Taxanes Efficacy in Castration Resistant Prostate Cancer

    Researchers explored the possibility of forced mitotic exit to elevate Taxane efficacy. Inactivation of the SAC component, mitotic checkpoint kinase Mps1/TTK with a small molecule inhibitor (Msp1i), potentiated efficacy of Taxanes treatment in both 2D cell culture and 3D prostasphere settings.
    [Cell Death & Disease]

    Full ArticleGraphical Abstract

    Vitamin D Deficiency Aggravates Growth and Metastasis of Prostate Cancer through Promoting EMT in Two β-Catenin-Related Mechanisms

    In vitro experiments showed that calcitriol, an active vitamin D3, inhibited migration and invasion in transforming growth factor-β1 -stimulated and -unstimulated PC-3 and DU145 cells.
    [The Journal of Nutritional Biochemistry]

    Abstract

    Exploiting Ligand Binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors

    Investigators applied the structural information of the ligand binding domain (LBD) dimerization interface of androgen receptor (AR) to screen in silico for AR inhibitors. A completely new binding site, the DIM pocket, was identified at the LBD dimerization interface.
    [Molecular Cancer Therapeutics]

    Abstract

    AZIN1 RNA Editing Alters Protein Interactions, Leading to Nuclear Translocation and Worse Outcomes in Prostate Cancer

    After comparison of wild-type Antizyme Inhibitor 1 (AZIN1) and edited AZIN1 (edAZIN1), scientists reported differential binding of edAZIN1 to a small set of proteins.
    [Experimental & Molecular Medicine]

    Full ArticleGraphical Abstract

    LncNAP1L6 Activates MMP Pathway by Stabilizing the m6A-Modified NAP1L2 to Promote Malignant Progression in Prostate Cancer

    Functional assays manifested that silencing of lncNAP1L6 hampered cell migration, invasion, and epithelial-mesenchymal transition (EMT) while overexpression of lncNAP1L6 exacerbated cell migration, invasion, and EMT.
    [Cancer Gene Therapy]

    Full ArticleGraphical Abstract

    LncRNA TMEM147-AS1/miR-133b/ZNF587 Axis Regulates Warburg Effect and Promotes Prostatic Carcinoma Invasion and Proliferation

    LncRNA TMEM147-AS1, miR-133b, and ZNF587 levels in prostatic carcinoma tissues and cells were detected by PCR or Western blot assays.
    [The Journal of Gene Medicine]

    Abstract

    Loss of miR-936 Leads to Acquisition of Androgen-Independent Metastatic Phenotype in Prostate Cancer

    Researchers found the downregulation of miR-936 in metastatic prostate cancer wherein its target ANXA2, a calcium-dependent phospholipid binding protein, was overexpressed.
    [Scientific Reports]

    Full Article

    Effects of Urinary Extracellular Vesicles from Prostate Cancer Patients on the Transcriptomes of Cancer-Associated and Normal Fibroblasts

    Patient-derived prostate fibroblast primary cultures PCF-54 and PCF-55 were established from two specimens of prostate cancer tissues.
    [BMC Cancer]

    Full Article

    Development, Evaluation, Pharmacokinetic and Biodistribution Estimation of Resveratrol Loaded Solid Lipid Nanoparticles for Prostate Cancer Targeting

    Trans-resveratrol using solid lipid nanoparticles was prepared by solvent emulsification evaporation technique and proceeded for evaluation like in vitro release, in vitro cytotoxicity, hemolysis and erythrocyte membrane integrity, platelet aggregation, and pharmacokinetic studies in rats.
    [Journal of Microencapsulation]

    Abstract
    Try proven workflows for your hPSC culture. Click to request your offer now.
    REVIEWS

    Oncological Outcomes of Cribriform Histology Pattern in Prostate Cancer Patients: A Systematic Review and Meta-Analysis

    The authors conducted a quantitative analysis of data from 31 studies describing the association between cribriform patterns at radical prostatectomy and the presence of extra-prostatic extension, seminal vesicle invasion, positive surgical margins, biochemical recurrence, or cancer specific mortality.
    [Prostate Cancer and Prostatic Diseases]

    Abstract
    INDUSTRY AND POLICY NEWS

    Novartis Receives Positive CHMP Opinion for Pluvicto® for Patients with Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

    Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorization for Pluvicto, a radioligand therapy, for the treatment of adult patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
    [Novartis Pharma AG (GlobeNewswire, Inc.)]

    Press Release

    Phanes Therapeutics Announces FDA IND Clearance for PT217, an Anti-DLL3/Anti-CD47 Bispecific Antibody Being Developed for Patients with Small Cell Lung Cancer and Other Neuroendocrine Cancers

    Phanes Therapeutics, Inc., a clinical stage biotech company focused on oncology, announced that it has received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47) bispecific antibody.
    [Phanes Therapeutics]

    Press Release

    Health Canada Approves Illuccix® for Prostate Cancer Imaging

    Telix Pharmaceuticals Limited announces that Health Canada has approved Illuccix® for use in staging and re-staging intermediate and high-risk prostate cancer and localizing tumour tissue in recurrent prostate cancer.
    [Telix Pharmaceuticals Limited]

    Press Release
    FEATURED EVENT

    Cell Bio 2022

    December 3 – 7, 2022
    Washington, DC, United States

    > See All Events

    JOB OPPORTUNITIES

    Senior Clinical Scientist – Oncology

    Merck & Co., Inc. – North Wales, Pennsylvania, United States

    Assistant/Associate Faculty Position – Cancer Research

    University of Colorado Denver – Aurora, Colorado, United States

    Research Fellow – Prostate and Kidney Cancer

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Clinical Director – Department of Health and Human Services

    NCI – Bethesda, Maryland, United States

    Research Officer – Mass Spectrometry Imaging

    Garvan Institute of Medical Research – Sydney, Australia

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter